Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $76.50 Consensus Target Price from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has earned an average rating of “Hold” from the seven analysts that are covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $76.50.

Several equities research analysts have recently issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday. Jefferies Financial Group reduced their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research report on Friday, January 30th.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the transaction, the vice president directly owned 41,048 shares in the company, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its holdings in Prestige Consumer Healthcare by 4.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock valued at $161,723,000 after acquiring an additional 119,459 shares during the last quarter. State Street Corp boosted its holdings in Prestige Consumer Healthcare by 1.4% in the fourth quarter. State Street Corp now owns 1,992,497 shares of the company’s stock valued at $122,917,000 after acquiring an additional 27,721 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Prestige Consumer Healthcare by 1.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock valued at $98,776,000 after acquiring an additional 21,085 shares during the last quarter. Morgan Stanley boosted its holdings in Prestige Consumer Healthcare by 6.3% in the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company’s stock valued at $74,209,000 after acquiring an additional 71,078 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Prestige Consumer Healthcare by 5.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company’s stock valued at $45,568,000 after acquiring an additional 35,126 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Up 2.1%

Shares of NYSE PBH opened at $58.97 on Thursday. The stock has a fifty day simple moving average of $61.89 and a 200-day simple moving average of $62.20. The stock has a market capitalization of $2.79 billion, a PE ratio of 15.60, a PEG ratio of 1.73 and a beta of 0.47. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a twelve month low of $51.24 and a twelve month high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same quarter last year, the company posted $1.22 EPS. Prestige Consumer Healthcare’s quarterly revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare will post 4.54 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).